---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-25-000069"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:15:36.508132+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Reports Q1 2025 Net Product Revenue of $16.5M, Up 129% from Q4 2024

## Summary
- Net product revenue for Q1 2025 reached $16.5 million, a 129% increase over $7.2 million in Q4 2024.
- ANKTIVA unit sales volume grew 150% in Q1 2025 compared to Q4 2024, with March volume up 69% over February.
- Nearly 200 urology practices are registering for ImmunityBio's recombinant BCG Expanded Access Program (EAP).
- Positive long-term results from the QUILT 3.032 study showed highest cystectomy avoidance in NMIBC space.
- ImmunityBio completed a $75 million equity financing in April 2025 to support operations.

## SEC filing metadata
- accession: 0001326110-25-000069
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/0001326110-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/ibrx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-25-000069
- JSON: https://secwatch.observer/filing/0001326110-25-000069.json
- Plain text: https://secwatch.observer/filing/0001326110-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.